A judge overseeing a lease dispute in relation to a Brisbane CBD office tower has slashed a $43.2 million statutory demand against construction company Grocon by more than two thirds, finding property management firm Dexus was unreasonable to demand payment just two business days after issuing its invoices.
Pitcher Partners has lost it challenge to a ruling socking it with a $5.6 million bill for an accounting error concealed from client Neville’s Bus Service, with an appeals court saying there was a “clear and principled basis” to require the accounting firm to pay the sum awarded for loss and damage to the transport company.
Certain executives of Australian companies might have to wait seven years to have their bonuses paid out under proposed changes to executive remuneration introduced by the Australian Prudential Regulation Authority designed to limit the risk of misconduct and align executive pay with long-term performance.
Defence shipbuilder Austal faces legal action by the corporate regulator challenging claims of privilege over documents sought as part of a probe into disclosures linked to cost overruns on the company’s $4 billion US Navy ship-building program.
The settlement of the Discovery Metals investor class action against KPMG has experienced another setback, after scheme administrator Grant Thornton flagged a potential conflict of interest in acting as a costs contradictor over Piper Alderman’s controversial $3.5 million legal bill.
A judge who this month faced strong criticism from an appeals court for his “egregious” conduct in a case, has stepped down from senior administrative roles on the Federal Circuit Court and will receive mentoring, the court confirmed Monday.
Mylan has launched a lawsuit against Cipla for allegedly copying the get-up of its blockbuster cholesterol drug Lipidil, after losing a bid to block Cipla and Sun Pharma from selling generic versions of the drug while it appeals a ruling invalidating several claims of its patents.
Patents at the centre of a high stakes IP dispute between tech giants Motorola and Hytera have significantly more than the necessary “scintilla of inventiveness” to be deemed valid, Motorola said on the first day of a month-long trial.
A unit of Boehringer Ingelheim has been given more time to oppose a proposed patent by rival drug maker Intervet, after the German drug company’s lawyers sent an email with the wrong opposition deadline.
Blue Sky Alternative Investments has reached a confidential settlement of its case against three former directors and two investment firms over an alleged raid on the fund manager’s confidential database.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
